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Many neuropeptides and their G-protein coupled receptors (GPCRs) are present within the
brain area involved in ventilatory and cardiovascular regulation but only a few mammalian
studies have focused on the integrative physiological actions of neuropeptides on these
vital cardio-respiratory regulations. Because both the central neuroanatomical substrates
that govern motor ventilatory and cardiovascular output and the primary sequence of
regulatory peptides and their receptors have been mostly conserved through evolution,
we have developed a trout model to study the central action of native neuropeptides on
cardio-ventilatory regulation. In the present review, we summarize the most recent results
obtained using this non-mammalian model with a focus on PACAP, VIP, tachykinins, CRF,
urotensin-1, CGRP, angiotensin-related peptides, urotensin-II, NPY, and PYY. We propose
hypotheses regarding the physiological relevance of the results obtained.
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INTRODUCTION
In addition to classical neurotransmitters, numerous brain neu-
ropeptides and their G-protein coupled receptors (GPCRs) have
been identified in several cardiovascular and ventilatory nuclei
(Fuxe et al., 1986). Considerable data have accumulated in
the literature concerning the central cardiovascular actions of
these neuropeptides in mammals but much less is known about
the roles of central neuropeptides on ventilatory regulation
(Niewoehner et al., 1983; Doi and Ramirez, 2008; Pilowsky et al.,
2009). Since the central ventilatory system and the cardiovascu-
lar system share some nuclei and mutually interact (Niewoehner
et al., 1983; Taylor et al., 1999, 2009; Mandel and Schreihofer,
2006; Dampney et al., 2008), it is crucial to determine the
integrative role of neuropeptides on these two vital regulatory
mechanisms. Fish are aquatic vertebrates that use their gills to
breathe, and mammals are vertebrates that breathe using their
lungs. Nevertheless, there are important similarities between fish
and mammals in the neuroanatomical networks and nervous
mechanisms that control the ventilatory and cardiovascular sys-
tems (Taylor et al., 1999, 2010a,b; Bolis et al., 2001). In addition,
neuropeptides appeared very early during evolution and the pri-
mary structures of these peptides and their receptors have been
Abbreviations: BRS, baroreflex sensitivity; CNS, central nervous system; CPG,
central pattern generator; DVN, dorsal motor nucleus of the vagus; HR, heart rate;
HRV, heart rate variability; IA, intra-arterial; ICV, intracerebroventricular; NPO,
preoptic nucleus; PDA, dorsal aortic blood pressure; VF, ventilation frequency; VA,
ventilation amplitude; VTOT, total ventilation.
generally well conserved from fish to mammals (Holmgren and
Jensen, 2001). Furthermore, in fish as in mammals, the neu-
ropeptidergic systems are frequently present within brain areas
involved in cardiovascular and ventilatory functions, including
the hypothalamus and the brainstem autonomic nuclei (Batten
et al., 1990; Dampney et al., 2005). Consequently, we have devel-
oped a trout model to gain insight into the effects of exogenously
administered synthetic replicates of endogenous neuropeptides
on ventilatory and cardiovascular functions in trout.
In this review, we summarize the neuroanatomical and func-
tional pathways involved in cardio-respiratory control in fish. We
describe the trout model and report methods to study the ven-
tilatory and cardiovascular responses to centrally administered
neuropeptides. We briefly summarize the available information
regarding the primary structures of the fish neuropeptides and
the similarities with their mammalian counterparts, the neu-
roanatomical location of the neuropeptides and their receptors
in the fish brains. The neuropeptides investigated in this pro-
gramme are those whose primary structures are known in the
trout and whose neuroananatomical distribution is well charac-
terized. We describe the ventilatory and cardiovascular actions
of these neuropeptides following their intracerebroventricular
(ICV) injection and we briefly contrast these central effects
with their actions following intra-arterial (IA) injection. Finally,
we propose hypotheses relating to the potential mechanisms of
actions and physiological significance of central neuropeptides in
the brain of the trout.
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NEURAL PATHWAYS REGULATING CARDIO-RESPIRATORY
FUNCTIONS IN FISH
The central control of cardiorespiratory functions in fish has been
previously described (Taylor et al., 1999). In fish, the visceral
sensory area in the medulla oblongata to which the chemore-
ceptor and baroreceptor afferent fibers project is homologous
to the nucleus tractus solitarius (NTS) of higher vertebrates
(Nieuwenhuys and Powels, 1983; Sundin et al., 2003a). The NTS
is the site where the first synapse on the chemo- and baro-
reflexes takes place. Rhythmic ventilatory movements in fish are
generated by a diffuse central pattern generator (CPG) whose
activity is modulated by inputs from the peripheral chemore-
ceptors and also from higher brain centers, including the mes-
encephalon and the forebrain (Taylor et al., 1999). The CPG
controls the activity of trigeminal Vth, facial VIIth, glossopha-
ryngeal IXth, and vagal Xth motor nuclei all of which drive
the breathing muscles (Taylor et al., 1999). There is a close
association between the neural mechanisms controlling the ven-
tilatory and the cardiovascular systems at the level of the medulla
oblongata (Taylor et al., 1999). Furthermore, anatomical and
functional links between the hypothalamus and the medullary
cardio-respiratory centers in teleosts have been described (Ariëns-
Kappers et al., 1936; Hornby and Demski, 1988). Electrical
stimulation of hypothalamic sites in the goldfish Carassius aura-
tus induces concomitant changes in ventilatory variables and
heart rate (HR) (Hornby and Demski, 1988). Within the brain-
stem, the cardiac vagal pre-ganglionic neurons are located within
the dorsal motor nucleus of the vagus (DVN). Some cardiac
vagal pre-ganglionic neurons are also present in a more lateral
position, probably constituting a primitive nucleus ambiguus.
However, little is known regarding the neurotransmitters and/or
neuropeptides and their receptors that permit integration of
the various inputs at the level of the brainstem to control the
final output motor impulses that ultimately govern the ventila-
tory and cardiovascular variables (Gilmour and Perry, 2007). In
the brainstem of the dogfish Squalus acanthias, catecholamines
regulate the electrical activity of respiratory neurons (Randall
and Taylor, 1991). In the channel catfish, Ictalurus puncta-
tus, glutamatergic pathways within the caudal part of the NTS
are essential for the control of ventilation and studies in the
shorthorn sculpin Myoxocephalus scorpius reveal that N-methyl-
D-aspartate (NMDA) receptors mediate ventilatory frequency
(VF), while kainate receptors mediate ventilatory amplitude (VA)
(Sundin et al., 2003b; Turesson and Sundin, 2003; Turesson et al.,
2010). In addition, it was shown that α-amino-3-OH-5-methyl-4-
isooxazole-propionic-acid (AMPA) receptors located within the
NTS control the parasympathetic activity to the heart and that
NMDA and non-NMDA receptors are involved in the hypoxia
activated sympathetic hypertension (Turesson et al., 2010). The
hearts of teleost fish receive both a cholinergic vagal innerva-
tion and an adrenergic sympathetic supply (Taylor et al., 1999).
Although humoral catecholamines increase HR after binding to
β-adrenoreceptors (Wood and Shelton, 1980), the functional role
of the nervous sympathetic system in teleost cardiac control is not
clearly recognized (Burnstock, 1969; Taylor et al., 1999). At rest,
the teleost heart is under strong inhibitory control mediated by
the vagus nerve acting on muscarinic cholinergic receptors on the
pacemaker cells (Laurent et al., 1983; Taylor, 1992; Taylor et al.,
1999).
THE TROUT MODEL
For the in vivo experiments, we use rainbow trout Oncorhynchus
mykiss (body wt 240–270 g) of both sexes. The experiments
were made on unanesthetized trout under controlled and
constant levels of oxygen partial pressure in water (PwO2),
pH and temperature, maintained at constant levels (PwO2 =
20 kPa; pH = 7.4 − 7.6; T = 10 − 11◦C). Experimental proto-
cols were approved by the Regional Ethics Committee in Animal
Experiments of Brittany, France (registration number: 07).
An overview of trout equipped with arterial and buccal
catheters, electrocardiographic (ECG) leads, and the ICV guide
is presented Figure 1. Examples of the recorded signals are also
plotted on the figure. The ventilatory and cardiovascular sig-
nals are processed off-line with custom-made programs writ-
ten in LabView 6.1 (Laboratory Virtual Instrument Engineering
Workbench, National Instruments).
THE VENTILATORY SIGNAL (FIGURE 1A)
A flared cannula is inserted into a hole drilled between the nares
such that its flared end is resting against the roof of the mouth.
This cannula is used to record any changes in buccal ventila-
tory pressure (Holeton and Randall, 1967). Segments free of any
movement artifacts on the ventilatory signal are selected and the
VF and VA are determined. VF is calculated from the first har-
monic of the power spectrum of the ventilatory signal using the
fast Fourier transform (FFT) algorithm. VA is calculated from the
difference between the maximal abduction phase and the maxi-
mal adduction phase for each of the ventilatory movements. The
net effect of the changes in VF and VA on ventilation is deter-
mined according to the formula VTOT = VF × VA where VTOT
is total ventilation. Thus, the overall ventilatory response is deter-
mined by the combined output of the VF and ventilatory stroke
volume (by approximation VA).
THE BLOOD PRESSURE SIGNAL (FIGURE 1B)
Catheterization of the dorsal aorta (Soivio et al., 1972) permits
the recording of the dorsal aortic blood pressure (PDA) and injec-
tion of various compounds, including the neuropeptides. Blood
is collected via this catheter for routine hematocrit determina-
tion and for measurement of the concentration of hormones in
plasma. The pulsatile PDA enables the measurement of systolic
blood pressure (SBP) and diastolic blood pressure (DBP). Mean
PDA is calculated as the arithmetic mean between the SBP and
the DBP. The detection of the SBP along the recordings together
with the R-R tachogram permits the determination of the cardiac
baroreflex response. The baroreflex has been evolutionary con-
served from Agnatha (lamprey) to humans (Bagshaw, 1985). The
baroreflex in fish, as in humans, is working spontaneously under
baseline conditions and also responds to adverse blood pressure
changes (Lancien and Le Mével, 2007; Karemaker and Wesseling,
2008). In fish, the baroreflex response is probably used as a mech-
anism to protect the delicate vasculature of the fish gill against
high blood pressure (Sundin and Nilsson, 2002). We evaluate the
cardiac baroreflex sensitivity (BRS) using both a time domain
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FIGURE 1 | The trout model used for testing the intracerebroventricular and intra-arterial effects of neuropeptides on (A) ventilatory signal; (B) blood
pressure signal; and (C) ECG signal. SBP, systolic blood pressure; DBP, diastolic blood pressure; ECG, electrocardiographic; ICV, intracerebroventricular. See
text for explanations.
method, the sequencemethod (Bertinieri et al., 1988; Lancien and
Le Mével, 2007) and a frequency domain method, the cross spec-
tral analysis technique (Parati et al., 2000; Lancien et al., 2011). In
teleost fish (Lancien and LeMével, 2007; Sandblom and Axelsson,
2011), as in mammals (Bertinieri et al., 1988), the parasympa-
thetic nervous system plays a crucial role in the short term cardiac
baroreflex response.
THE ELECTROCARDIOGRAPHIC (ECG) SIGNAL (FIGURE 1C)
Two ECG AgCl electrodes are subcutaneously implanted ven-
trally and longitudinally at the level of the pectoral fins. After
amplification, the ECG signal, which is very similar to the
human ECG, displays its different waves (P, Q, R, S, T) (Satchell,
1991). The QRS complex is the largest deflection and the R
waves are routinely measured to determine HR. The R-R inter-
val of the ECG can be used to plot the tachogram and to
quantify the heart rate variability (HRV) using either the FFT
algorithm (for review see Task Force of the European Society
of Cardiology, and the North American Society of Pacing and
Electrophysiology, 1996) or the Poincaré plot (Brennan et al.,
2001). HRV reflects modulation on a beat to beat basis of the car-
diac sinus node activity by both limbs of the autonomic nervous
system. The high frequency component of the HRV in humans
reflects respiratory sinus arrhythmia and provides information
primarily on the degree of vagal tone on the heart (Médigue
et al., 2001). Interestingly, studies of HRV in teleost fish demon-
strate that the parasympathetic nervous system is the main, or
even the only, contributor to HRV (Altimiras et al., 1995; Le
Mével et al., 2002; Grossman and Taylor, 2007). Nevertheless,
the physiological significance of HRV in teleost fishes is poorly
understood.
THE ICV GUIDE
Fish do not possess large and expanded cerebral hemispheres with
a developed neocortex (Nieuwenhuys et al., 1998). Consequently,
these animals offer the opportunity to insert directly, under
stereomicroscopic guidance, a 25-gauge needle fitted with a PE-10
polyethylene catheter between the two habenular ganglia toward
the third ventricle until its tip lies between the two preoptic nuclei
(NPO) (Le Mével et al., 2009a). The method is rapid and accu-
rate since no stereotaxic placement is needed. In addition, no
post-injection confirmation of the injected site is required. The
rationale for this ICV implantation between the two NPO is
that neuropeptides, directly or after diffusion through the cere-
brospinal fluid, can access sites which are known to be critical to
ventilatory and cardiovascular control. In teleost fish, as in mam-
mals, these are the hypothalamus and the brainstem (Hornby and
Demski, 1988; Taylor et al., 1999; Dampney et al., 2008).
EFFECTS OF INTRACEREBROVENTRICULAR INJECTIONS OF
NEUROPEPTIDES
PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP)
AND VASOACTIVE INTESTINAL PEPTIDE (VIP)
PACAP and VIP belong to the secretin-glucagon superfamily of
peptides (Sherwood et al., 2000). PACAP is found in two forms,
a 38 amino-acid peptide (PACAP-38) and the C-terminally trun-
cated 27 amino-acid peptide (PACAP-27). PACAP and VIP share
sequence similarity and, in mammals, these peptides exert their
actions by binding to three receptors, PAC1, VPAC1, and VPAC2
(Laburthe et al., 2007). Within the brains of mammals, PACAP
and VIP are known to control multiple physiological functions
including some cardiovascular and ventilatory processes (Wilson
and Cumming, 2008; Vaudry et al., 2009).
PACAP and VIP appeared very early during evolution and
the primary structure of these peptides and their receptors have
been remarkably well conserved from fish to mammals (Wong
et al., 1998; Sherwood et al., 2000; Montpetit et al., 2003).
Within the central nervous system (CNS) of teleosts, PACAP-
and VIP-like immunoreactivities are localized mainly in neu-
ronal perikarya of the diencephalon at the level of the NPO.
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Their fibers project not only into the adenohypophysis (Matsuda
et al., 1997; Montero et al., 1998; Wong et al., 1998) but also
toward many extra hypothalamo-hypophysial areas such as the
mesencephalon and themedulla oblongata (Montero et al., 1998).
These observations suggest that PACAP and VIP act not only as
hypophysiotropic hormones (Montero et al., 1998; Wong et al.,
1998) but also as neurotransmitters, and/or neuromodulators.
In the goldfish, peripheral PACAP reduces food intake (Matsuda
et al., 2006). We also demonstrated that trout PACAP-27 and
trout VIP act on the CNS to increase ventilation (Le Mével
et al., 2009b) and to reduce the cardiac BRS (Lancien et al.,
2011).
After ICV injection, PACAP (25–100 pmol) evokes a dose- and
time-dependent elevation of VF and VA. Consequently, the net
effect of the peptide is a hyperventilatory response involving a
gradual and significant dose-dependent increase in VTOT. The
threshold dose for an effect of PACAP on VF is 100 pmol, but a
significant effect on VA and VTOT is seen at 50 pmol and this
latter effect is observed 15min after the injection of the peptide.
The actions of PACAP on the ventilatory variables are long-lasting
since values have not returned to baseline levels by the end of
the post-injection period of 25min. Themost pronounced action
of PACAP is evoking hyperventilation through an increase in VA
rather than VF. For instance, after 50 and 100 pmol PACAP this
maximal change in VA, expressed as a percentage of the pre-
injection value, reaches about 100 and 200%, respectively, while
the elevation of VF is only about 10 and 35% (Le Mével et al.,
2009b).
Upon ICV injection, the effects of trout VIP on the ven-
tilatory variables are quite different from those following ICV
injection of PACAP. VIP does not produce a significant increase
in VF and VA but nonetheless the resultant action of this pep-
tide is a small, transient but significant elevation of VTOT at the
highest dose tested. Moreover, statistical analysis of the results
obtained following ICV injection indicates that the maximum
increase in VF, VA, and VTOT after ICV injection of 100 pmol
PACAP relative to the pre-injection values is about 2.5-fold
higher than the maximum ventilatory effects of the same dose
of VIP.
After ICV injection, only the highest dose of PACAP produces
a weak, but significant, sustained increase in PDA. However, there
is no significant change in HR. ICV injections of VIP do not cause
any change in either PDA or HR. The greater action of PACAP on
ventilation and blood pressure compared with VIP suggests that
PACAP may bind preferentially to PAC1 receptors rather than to
VPAC receptors. The lack of HR response to elevation of blood
pressure suggests that the cardiac BRS is depressed following cen-
tral PACAP. Compared with vehicle, ICV injections of PACAP and
VIP (25–100 pmol) dose-dependently reduce the cardiac BRS to
the same extent with a threshold dose of 50 pmol for a significant
effect (Lancien et al., 2011).
In contrast to their ICV effects, IA injections of PACAP and
VIP at doses of 25–100 pmol produce no change in the ventila-
tory variables. Peripherally injected PACAP does not cause any
significant change either in PDA or in HR, but bolus peripheral
injection of VIP produces a robust dose-dependent and sustained
hypertensive response without any change in HR.
NEUROPEPTIDE GAMMA (NPγ), NEUROKININ A (NKA) AND
SUBSTANCE P (SP)
The tachykinins are a family of biologically active peptides that
are characterized structurally by the common carboxy-terminal
pentapeptide sequence Phe-Xaa-Gly-Leu-Met-NH2. This C-
terminally amidated sequence is of primary importance for
the interaction with the tachykinin receptors (Conlon, 2004).
In mammals, SP, NKA, NPγ, and neuropeptide K (NPK) are
encoded by the single copy preprotachykinin A gene. Neurokinin
B is derived from the preprotachykinin B gene while the pre-
protachykinin C gene encodes three peptides (hemokinin 1,
endokinin C, and endokinin D) with limited structural similar-
ity with SP (for references, see Conlon, 2004). The tachykinins
exert their actions by binding to GPCRs that are widely dis-
tributed within vascular, endocrine and nervous tissues. SP is
the preferential agonist of the NK-1 receptor, NKA along with
NPγ and NPK are regarded as endogenous ligands of the NK-2
receptor, and NKB is the preferred agonist of the NK-3 receptor
(Patacchini and Maggi, 2004). In mammals, there is strong evi-
dence for the importance of CNS tachykinins in the control of
respiration (Gray et al., 1999). In addition, central tachykinins are
involved in cardiovascular regulation, neuroendocrine secretion,
pain transmission, and in certain behavioral responses (Satake
and Kawada, 2006).
Orthologs of the mammalian tachykinins have been isolated
and structurally characterized in a wide range of tetrapod and
non-tetrapod species (for references, see Conlon, 2004). In par-
ticular, SP (Jensen and Conlon, 1992), NKA (Jensen and Conlon,
1992), and NPγ (Jensen et al., 1993) have been purified from
tissues of the rainbow trout O. mykiss. Neuroanatomical studies
have revealed the presence of tachykinin-like immunoreactivity
in neuronal cell bodies and fibers throughout the brains of sev-
eral teleost fish, including the trout (Vecino et al., 1989; Batten
et al., 1990; Holmqvist and Ekstrom, 1991; Moons et al., 1992)
together with high density of tachykinin binding sites from the
hypothalamus to the medulla oblongata (Moons et al., 1992).
We recently demonstrated that, after ICV injection, exogenously
administered trout tachykinins are differentially implicated in the
neuroregulatory control of ventilation in trout (Le Mével et al.,
2007).
Compared with ICV injection of vehicle, NPγ (25–100 pmol)
evokes a gradual elevation of VF but a progressive dose-
dependent reduction of VA. Therefore, the net effect of the pep-
tide is a hypoventilatory response involving a significant decrease
in VTOT. The threshold dose for an effect of NPγ on VF, VA, and
VTOT is 50 pmol and this is observed 15min after the injection
of the peptide (Figure 2A). Interestingly, in some trout, the ICV
injection of 100 pmol NPγ was followed by a dramatic reduction
in VA to near the noise level of the recording system for peri-
ods of 10–20 s, giving the appearance of an apneic response. All
actions of NPγ on the ventilatory variables are of long duration,
since parameters do not return to baseline values by the end of
the recording period.
In contrast to the action of NPγ, the effects of
SP(50–250 pmol) on ventilation are not dose dependent
and only the highest dose of SP (250 pmol) produces a significant
elevation of VF, a significant reduction of VA, and a resultant
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FIGURE 2 | Recording traces of 30 s duration from two unanesthetized
trout illustrating the changes observed in ventilatory movements
(ventilation), pulsatile dorsal aortic blood pressure (PDA), and
electrocardiographic (ECG) signals between the pre-injection period
(0–5min) and the post-injection period (20–25min) after
intracerebroventricular (ICV) injection of (A) 50pmol trout neuropeptide
gamma (NPγ) or (B) 50pmol trout calcitonin gene-related peptide
(CGRP). Note that ICV injection of NPγ produces an impressive reduction in
the ventilatory amplitude but a slight increase in the ventilatory frequency. In
contrast, ICV CGRP evokes a potent increase of the ventilation rate and
amplitude. Only the ICV injection of CGRP causes a substantial elevation of
blood pressure and heart rate.
significant decrease of VTOT. The changes in these parameters
reach significance 10–15min after ICV injection.
As with SP, the effect of NKA (50–250 pmol) on the venti-
latory variables are relatively minor, with only the highest dose
(250 pmol) producing a significant decrease in VA and an overall
significant fall in VTOT. This action of NKA is of short duration
with VA returning rapidly to baseline values.
None of the three tachykinin peptides produce significant
changes in mean PDA or HR following ICV injection. Further
studies are required to determine whether the central action of
NPγ on ventilatory variables in trout involves interaction with
a receptor that resembles the mammalian NK-2 receptor more
closely than the NK1-receptor.
Because centrally controlled cardiorespiratory coupling con-
tributes to HRV in teleost fish (Grossman and Taylor, 2007),
we made the assumption that changes in the VF after central
injection of NPγ and SP, but not NKA, also produce changes in
HRV (Lancien et al., 2009). Compared to vehicle-injected trout,
Poincaré plot analysis of HRV demonstrates that ICV injection
of NPγ dose-dependently increases HRV. SP evokes a significant
elevation of HRV but only at the highest dose (250 pmol). In
contrast, NKA is without any effect on HRV. The physiological
significance of HRV in teleost fish is poorly understood. Recent
studies favor the hypothesis that HRV may be an important
component of the mechanisms optimizing the efficiency of res-
piratory gas exchange over the counter-current at the gill lamellae
(Grossman and Taylor, 2007). Taken together, our data are con-
sistent with a possible selective central action of NPγ on neuronal
networks implicated in the control of cardiorespiratory coupling
in teleost fish.
IA injections of NPγ, SP or NKA at doses of 50–250 pmol pro-
duce no change in any of the ventilatory variables. However, all
three tachykinins at their highest dose of 250 pmol cause a signif-
icant increase in mean PDA and, except for NPγ, a concomitant
and significant fall in HR.
CORTICOTROPIN-RELEASING FACTOR (CRF) AND UROTENSIN-I (U-I)
CRF, a 41-amino acid peptide originally isolated from ovine
hypothalamus (Vale et al., 1981), plays a key role in regulating
the release of adrenocorticotropic hormone from the pituitary
during stress. In mammals, CRF and the CRF-related peptide
urocortin 1, an ortholog of the fish U-I (Vaughan et al., 1995;
Barsyte et al., 1999), are also known to play a crucial neurotropic
role in the CNS in coordinating the autonomic and behavioral
responses to stressful situations (Koob and Heinrichs, 1999). In
mammals, the actions of the CRF-family peptides are mediated
by two types of G-protein-coupled receptors: CRF type 1 recep-
tor (CRF-R1) and CRF type 2 receptor (CRF-R2) (Bale and Vale,
2004). CRF, urocortin-1, and the non-mammalian CRF-related
peptides U-I, and sauvagine (SVG) bind with similar affinity to
CRF-R1 while CRF has only a low affinity for CRF-R2. U-I, SVG,
and the urocortins bind with high affinity to CRF-R2. In mam-
mals including humans, CRF immunoreactivity (Swanson et al.,
1983) and CRF receptors (Bale and Vale, 2004) are widely dis-
tributed in brain areas involved in the control of cardiovascular
regulation and breathing movements. After ICV administration,
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CRF and urocortin 1 induce marked changes in cardiovascular
variables (Parkes et al., 2001) and CRF acts centrally to produce a
strong stimulatory effect on ventilatory movements (Bennet et al.,
1990).
The CRF family of peptides and their receptors are of ancient
origin (Chang and Hsu, 2004). In teleost fish, CRF, U-I, CRF
receptors, and CRF binding protein are present not only in neu-
rons of the preoptic region and hypothalamus (Olivereau and
Olivereau, 1990) but also in extra-hypothalamic brain regions
including the telencephalon and the posterior brain (Batten et al.,
1990; Bernier et al., 1999a; Lovejoy and Balment, 1999; Alderman
et al., 2008). Taken together, these neuroanatomical findings raise
the possibility that CRF and U-I in teleosts also exert extra-
hypothalamo-hypophyseal actions and mediate some autonomic
and/or behavioral effects within the brain. In fact, physiologi-
cal data have indicated that, after ICV injection, CRF and U-I
are implicated in the autonomic regulation of the cardiovascu-
lar system (for review see Le Mével et al., 2006), the control of
locomotor activity (Clements et al., 2002) and in the regulation
of food intake (for review see Bernier, 2006). Our results demon-
strate that CRF and U-I also produce a potent hyperventilatory
response when injected centrally in trout (Le Mével et al., 2009a).
After ICV injection, trout CRF (1–10 pmol) evokes both grad-
ual and dose-dependent elevations of VF and VA. The net effect
of the peptide is, therefore, a hyperventilatory response involving
a significant dose-dependent elevation in VTOT. The minimum
dose to elicit a statistically significant response in both ventilatory
variables is 5 pmol and this is observed 15min after the injection
of the peptide. In contrast to the sustained action of ICV injec-
tion of CRF on VF and VA, a significant stimulatory action of
trout U-I (1–10 pmol) on these two variables appears only after
ICV injection of the highest dose of peptide tested. VTOT also
indicates that the significant hyperventilatory action of U-I is
delayed by 10min (U-I, 5 pmol) and 5min (U-I, 10 pmol) com-
pared to corresponding doses of CRF. Moreover, the maximum
increase in VTOT after ICV injection of CRF relative to the pre-
injection value is 2-fold higher than the hyperventilatory effect of
U-I during the 25–30min post-injection period.
At the dose of 5 pmol, only CRF transiently increases PDA, but
a clear sustained hypertension is observed for the highest dose of
10 pmol of CRF and U-I. ICV injection of either CRF or U-I has
no significant effect on HR for all doses tested.
ICV administration of alpha helical CRF9−41 (ahCRF9−41)
alone (50 pmol) does not affect the baseline ventilatory and car-
diovascular variables. However, pre-treatment of the trout with
this CRF antagonist at a dose ratio of ahCRF9−41: CRF of 10:1
delays and significantly reduces (by at least 3-fold) the CRF-
induced increase in VF, VA, and VTOT and inhibits CRF-induced
elevation in PDA. In fish, the pharmacological characteristics of
the CRF receptors are quite different from their mammalian
counterparts (see above). In catfish, where a third CRF receptor
(CRF-R3) has been identified (Arai et al., 2001), CRF-R1 binds
CRF, U-I, and SVG with similar affinity, while CRF-R2 preferen-
tially binds SVG. CRF-R3 binds CRF with a 5-fold higher affinity
than U-I and SVG (Arai et al., 2001). Pohl et al. (2001) concluded
that, in Chum salmon, neither CRF-R1 nor CRF-R2 could dis-
criminate between CRF and U-I. The lack of an intrinsic effect
of ahCRF9−41 when injected centrally suggests that endogenous
CRF and U-I are not involved in the regulation of VA and VF
in baseline situations. The fact that this antagonist significantly
reduces the central hyperventilatory effects of exogenous CRF
is indicative of a selective receptor-mediated hyperventilatory
action of CRF in the brain of the trout. However, the type of CRF
receptor involved cannot be determined at this time.
After IA injection, CRF and U-I are devoid of any ventilatory
or cardiovascular activities except a transient increase in blood
pressure at the highest dose of U-I (50 pmol).
CALCITONIN GENE-RELATED PEPTIDE (CGRP)
The 37-amino- acid peptide CGRP is derived from the tissue-
specific splicing of the primary transcript of the calcitonin
gene (Amara et al., 1982). CGRP is thus a member of the
calcitonin/CGRP peptide family that includes adrenomedullin
(AM), adrenomedullin-2 (or intermedin), amylin, and calcitonin
receptor-stimulating peptide (Ogoshi et al., 2006; Sawada et al.,
2006). CGRP binds to a seven transmembrane G-protein-coupled
calcitonin receptor-like receptor that is complexed with one of
three receptor activity-modifying proteins (Tam and Brain, 2006).
In mammals, CGRP and its receptors are widely distributed
throughout the peripheral and central CNS. In the CNS, CGRP
acts as a neurotransmitter and/or neuromodulator involved in
multiple physiological and behavioral processes including the
hypothalamic regulation of feeding (Krahn et al., 1984). In addi-
tion, CGRP regulates the local vasodilation of cerebral vessels
contributing to the pathophysiology of migraine headache and
the peptide modulates pain responses at the level of the spinal
cord (Tam and Brain, 2006). Central CGRP also plays a role in
the autonomic regulation of the cardiovascular system. In con-
trast to its hypotensive effect in the periphery, ICV injection of
CGRP produces a hypertensive response by activating the sympa-
thetic nerves in rats (Fisher et al., 1983) and CGRP augments the
baroreflex controls of renal sympathetic nerve activity and HR in
the unanesthetized rabbit (Matsumura et al., 1999).
CGRP has an ancient evolutionary history. In fish, cDNAs
encoding for CGRP have been isolated from a number of species
(Jansz and Zandberg, 1992; Clark et al., 2002; Ogoshi et al., 2006;
Martinez-Alvarez et al., 2008) and CGRP mRNA is expressed
in peripheral and central tissues (Clark et al., 2002; Martinez-
Alvarez et al., 2008). Moreover, the primary sequence of the
peptide has been highly conserved from fish to humans (Shahbazi
et al., 1998). As in many cerebral regions, the hypothalamus
expresses CGRP mRNA (Martinez-Alvarez et al., 2008) and some
CGRP-like immunoreactive fibers represent ascending projec-
tions from brainstem areas involved in autonomic functions
(Batten and Cambre, 1989; Batten et al., 1990). Interestingly,
in the goldfish Carassius auratus and in the puffer fish Fugu
rubripes (Clark et al., 2002) the strongest expression of calci-
tonin/CGRP transcripts was observed in the posterior brain at
the level of autonomic nuclei and spinal cord. In addition, CGRP
receptors are present within the brain and heart of the flounder
Paralichthys olivaceus (Suzuki and Kurokawa, 2000). Collectively
these neuroanatomical data support a role for CGRP not only
in neuroendocrine function and behavior but also in autonomic
and cardiovascular regulation in fish. The anorexigenic action of
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centrally administered CGRP in the goldfishCarassius auratus has
been previously described (Martinez-Alvarez et al., 2009). The
cardio-ventilatory actions of centrally administered trout CGRP
in trout has been recently described (Le Mével et al., 2012).
ICV administration of CGRP (1–50 pmol) evokes a dose- and
time-dependent elevation of VF and VA. As a result, the net effect
of the peptide is a hyperventilatory response involving a gradual
and significant dose-dependent increase in VTOT. The threshold
dose for an effect of CGRP on VF is 50 pmol but only 5 pmol for
VA (Figure 2B). As for many neuropeptides, the actions of CGRP
on these ventilatory variables are long-lasting since values had
not returned to baseline levels by the end of the post-injection
period of 25min. This observation suggests that CGRP may act
as a long-term hyperventilatory peptide in vivo. The most pro-
nounced action of CGRP is evoking hyperventilation through an
increase in VA instead of VF. For instance at a dose of 50 pmol,
during the 15–20min post-injection period when VTOT is max-
imal and increased by 300% from baseline value, the change in
VA, expressed as a percentage of pre-injection value, is more than
200% while the elevation of VF is only about 30%.
After ICV injection, CGRP produces a significant dose-
dependent and sustained increase in PDA but the increase in HR
does not reach the level of statistical significance. The receptor(s)
mediating the ventilatory and cardiovascular action of CGRP in
trout have not been determined. In eel, the paralogs AM2 and
AM5 exhibit different central cardiovascular responses suggesting
that theymay act through different receptors (Ogoshi et al., 2008).
In contrast to its ICV effects, IA injections of CGRP at
doses of 5–50 pmol produce no change in VF, VA, or VTOT.
Nonetheless, peripherally injected CGRP causes an overall robust,
dose-dependent and sustained hypertensive response without any
change in HR. IA injection of the highest dose of CGRP causes at
first a rapid but transient decrease in PDA followed by a hyper-
tensive phase that does not return to the pre-injection level until
60min.
ANGIOTENSIN PEPTIDES
Data from mammalian studies have demonstrated that
angiotensin II (Ang II) and angiotensin III (Ang III) are
the two main effector peptides of the brain renin-angiotensin
system (RAS). However, angiotensin IV (Ang IV) and to a
lesser extend angiotensin 1–7 (Ang 1–7) are also implicated
in various physiological functions, particularly body fluid
homeostasis and cardiovascular regulation (Paul et al., 2006;
Fyhrquist and Saijonmaa, 2008). Ang II and Ang III bind to
angiotensin receptor type 1 (AT1) and type 2 (AT2). Ang IV
binds exclusively to angiotensin receptor type 4 (AT4). The type
of receptor that mediates the actions of Ang 1–7 is somewhat
controversial. Studies on the effects of the RAS on ventilation
are limited and only the action of Ang II has been explored
in mammals. In both anaesthetized and unanaesthetized dogs
(Potter and McCloskey, 1979; Ohtake and Jennings, 1993) and in
unanaesthetized rabbits (Potter and McCloskey, 1979) but not
in unanaesthetized Sprague-Dawley rats (Walker and Jennings,
1996), Ang II stimulates ventilation through a central mechanism
that is independent of baroreceptor or chemoreceptor stimula-
tion (Potter and McCloskey, 1979). In spontaneous hypertensive
rats (SHR), but not in normotensive control Wistar-Kyoto
rats, intravenous injection of the Ang II receptor antagonist,
saralasin, has a depressant action upon ventilation (O’Connor
and Jennings, 2001). Because SHR rats exhibit high brain RAS
activity compared with normotensive control Wistar-Kyoto
rats, the authors speculated that central Ang II is involved in the
control of respiration only in SHR rats. However, in anaesthetized
Sprague-Dawley rats, intracisternal ANG II provokes a decrease
that becomes less when the doses of Ang II are increased (Aguirre
et al., 1991) and ICV injection of saralasin reduces respiratory
rate and respiratory rate variability in Wistar rats (Olsson et al.,
2004). These data indicate that the brain RAS plays a role in the
control of ventilation in mammalian species. In humans, Ang II
may be implicated in the regulation of the respiratory sensitivity
during pregnancy but the mechanism involved in this effect has
not been elucidated (Wolfe et al., 1998).
The RAS has an ancient evolutionary history and most of its
components are present in lampreys, elasmobranchs, and teleosts
(Olson, 1992; Takei et al., 1993; Nishimura, 2001; Rankin et al.,
2004; Wong and Takei, 2011). In contrast to the well known
peripheral cardiovascular and osmoregulatory hormonal actions
of Ang II (Olson, 1992; Le Mével et al., 1993; Bernier et al., 1999b;
Takei and Balment, 2009), studies in fish on the central action
of Ang II are sparse. Furthermore, two Ang II isoforms [Asn1]-
and [Asp1]-Ang are present in plasma and tissues (Conlon et al.,
1996; Wong and Takei, 2012) but the physiological roles of the
latter form have only been recently explored (Lancien et al.,
2012). Central administration of [Asn1]-Ang II into the third
or fourth ventricle of the eel Anguilla japonica induces drink-
ing (Kozaka et al., 2003) and increases HR and blood pressure
(Nobata et al., 2011). This procedure elevates HR and blood
pressure but reduces both HRV and the cardiac BRS sensitivity
in the trout (Le Mével et al., 1994, 2002, 2008b; Lancien et al.,
2004b; Lancien and Le Mével, 2007) In addition, local injection
of [Asn1]-Ang II within the DVN of the trout potently enhances
HR but only weakly increases blood pressure (Pamantung et al.,
1997). Taken together, these results demonstrate that in the brains
of teleosts, as in mammals, Ang II may act as a neuromodulator
or a neurotransmitter involved in key osmoregulatory and car-
diovascular regulations. Recently, the cardio-ventilatory actions
of exogenously administered [Asn1]-Ang II, [Asp1]-Ang II, Ang
III, Ang IV, and Ang 1–7 within the third ventricle of the trout
brain have been described (Lancien et al., 2012). In addition,
the angiotensin peptides produced in the brain and circulating
in plasma of trout were characterized using a high performance
liquid chromatography (HPLC) system that can separate these
peptides (Lancien et al., 2012; Wong and Takei, 2012).
After ICV injection (5–50 pmol), [Asn1]-Ang II and [Asp1]-
Ang II gradually elevate VTOT through a selective stimulatory
action on VA. However, the hyperventilatory effect of [Asn1]-Ang
II is 3-fold higher than the effect of [Asp1]-Ang II at the 50 pmol
dose. Ang III, Ang IV, and Ang 1–7 (25–100 pmol) are without
effect on the ventilatory variables. In addition, both Ang II pep-
tides and Ang III dose-dependently increase PDA and HR. These
results suggest that the N- and C-terminal amino acid residues of
Ang II are important for full effect on the central receptor(s) that
mediate(s) hyperventilation and cardiovascular actions. It was
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previously proposed that in trout, [Asn1]-Ang II was the prod-
uct of angiotensinogen cleavage in plasma but that this peptide
is converted to [Asp1]-Ang II by plasma asparaginase (Conlon
et al., 1996). In eel plasma, asparaginase activity is low and the
conversion seems to occur in the tissues such as liver and kid-
ney with angiotensinogen, not Ang II, as substrate (Wong and
Takei, 2012). In brain tissue, comparable amounts of [Asn1]-Ang
II and [Asp1]-Ang II were detected (ca. 40 fmol/mg brain tissue)
but Ang III was not present, and the amount of Ang IV was about
8-fold lower than the content of the Ang II peptides. In plasma,
Ang II peptides were also the major angiotensins (ca. 110 fmol/ml
plasma), while significant but lower amounts of Ang III and Ang
IV were present. These results demonstrate that the two Ang II
peptides are present in trout plasma and brain tissue and suggest
that the conversion Asn1 → Asp1occurs not only in plasma but
also in brain. It has been proposed that the teleost AT receptor
is an AT1-like receptor (Russell et al., 2001). The demonstration
that both Ang II peptides and Ang III elevate PDA and HR while
the other angiotensins were without action supports the idea that
an AT1-like receptor might also be involved in the central car-
diovascular actions of Ang II and Ang III. A novel receptor that
binds specifically or with a higher affinity to the Ang II peptides,
but not the truncated forms, might mediate the ventilatory effect
of the brain RAS in trout.
Within the brain of the trout, [Asn1]-Ang II affects not only
the mean HR but also the beat to beat change in R-R intervals
of the ECG since ICV injection of the peptide reduces HRV (Le
Mével et al., 2002) and the cardiac BRS (Lancien and Le Mével,
2007).
None of the angiotensin peptides injected peripherally alter
any of the ventilatory variables but the two Ang II isoforms and
to a lesser extent Ang III provoke a pressor response. The con-
comitant decrease in HR following the IA injections of these
angiotensins is not significant. In addition, Ang IV and Ang 1–7
are without effect on the cardiovascular variables. Collectively,
these results support the view that the N- and C-terminal residues
of the Ang II peptides play a role in optimal interaction with
the putative cardiovascular angiotensin receptor in trout vascular
tissue (Nishimura, 2001).
UROTENSIN II (U-II)
U-II is a cyclic neuropeptide that was originally isolated from
the caudal neurosecretory system of the teleost fish Gillichthys
mirabilis on the basis of its smooth muscle-stimulating activity
(Pearson et al., 1980; Bern et al., 1985). U-II is widely expressed
in peripheral and nervous structures of species from lampreys to
mammals including humans (Vaudry et al., 2010). It has now
been demonstrated that U-II belongs to a family of structurally
related peptides that include U-II and the UII-related peptides
(URPs), URP, URP-1, and URP-2. In the teleost lineage, four
U-II/URP paralogs are present but only two of these ancestral
genes, U-II and URP, are found in tetrapods (Quan et al., 2012).
U-II, URP, and URP isoforms exhibit the same cyclic hexapep-
tide core sequence (Cys-Phe-Trp-Lys-Tyr-Cys) while the N- and
C-terminal regions are highly variable (Lihrmann et al., 2006;
Conlon, 2008). Studies on UII/URP/URP-2 gene expression in
teleosts and tetrapods suggest that U-II, URP, and URP-2 exert
different functions (Parmentier et al., 2011). In teleost fish URP,
URP-1, and URP-2 mRNA occur both in brain and spinal cord
(Parmentier et al., 2008; Nobata et al., 2011) but in the eel,
Anguilla japonica the U-II gene is exclusively expressed in the
urophysis (Nobata et al., 2011). In tetrapods, the U-II gene is
expressed primarily in motoneurons of the brainstem and spinal
cord (Vaudry et al., 2010). U-II has been identified as a specific
natural ligand of the orphan, G-protein-coupled receptor GPR14
(now renamed the UT receptor) inmammals (Vaudry et al., 2010)
and in teleost fish (Lu et al., 2006). U-II andURP both activate the
UT receptor with the same potency. The cardiovascular effects of
centrally administered U-II and URP in trout and eel have been
analyzed. In trout and eel, only a relatively high dose of U-II
(500 pmol) evokes an increase in PDA with variable action on HR
(Le Mével et al., 1996; Nobata et al., 2011). In addition, the cen-
tral vasopressor action of URP in the eel is equally efficacious but
less potent than the action of U-II (Nobata et al., 2011). The brain
structures controlling the ventilatory system in trout seem to be
more sensitive to the central action of U-II as only a 50 pmol dose
of the peptide produces an hyperventilatory response through a
significant increase in VF and VA (Lancien et al., 2004a). At this
dose, U-II produces a long-lasting increase in locomotor activity
(Lancien et al., 2004a). The effects of central URP and URP iso-
forms on the ventilatory and cardiovascular systems in trout have
not yet been determined.
IA injection of U-II and URP in trout and eel evokes an ele-
vation in PDA. In both species, the hypertensive effect of U-II is
longer-lasting than that of URP (Le Mével et al., 2008a; Nobata
et al., 2011). In trout, U-II only provokes a dose-dependent
bradycardia (Le Mével et al., 1996, 2008a), while in the eel, U-II
and URP significantly increase HR (Nobata et al., 2011). U-II is
devoid of ventilatory actions following systemic injection in trout
(unpublished observations).
NEUROPEPTIDE TYROSINE (NPY) AND PEPTIDE TYROSINE
TYROSINE (PYY)
NPY and PYY are two members of the pancreatic polypeptide
family of regulatory peptides. These two 36-amino acid peptides
contain a tyrosine residue at their N- and C-termini. NPY is the
most abundant peptide within the CNS of mammals. The peptide
and its GPCRs, designated Y1, Y2, Y4, Y5, and Y6, are widely dis-
tributed in nerve terminals throughout the brain (Dumont and
Quirion, 2006). NPY-like immunoreactivity has been demon-
strated in many noradrenergic and adrenergic neurons of the
medulla oblongata (Fuxe et al., 1986). NPY-containing cell bod-
ies are found in the lateral hypothalamus and NPY innervation
of the paraventricular nucleus (PVN) of the hypothalamus arises
from the medulla oblongata (Dumont and Quirion, 2006). In
mammals, including rat, mouse, sheep, pig, rabbit, and pigeon,
NPY hasmany neuroendocrine regulatory effects within the brain
including an orexigenic action and regulation of food intake,
anxiety, circadian rhythms, and memory. The central actions
of NPY on cardiorespiratory functions remain unclear due to
the fact that activation of different NPY receptors have oppo-
site effects on cardiorespiratory variables (Fuxe et al., 1983; Scott
et al., 1989; Morton et al., 1999). NPY is also present in periph-
eral organs, notably in blood vessels and heart. PYY is primarily
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located in endocrine cells of the lower intestine. In mammals,
these two peptides are also involved in peripheral vasoregulation
(Zukowska-Grojec et al., 1987; Playford et al., 1992).
NPY and PYY are present in both peripheral and brain tis-
sues in fish (Jensen and Conlon, 1992; Danger et al., 1991). Seven
NPY receptors subtypes (Y1, Y2, Y4–Y8) bind both NPY and PYY
in fish (Salaneck et al., 2008). ICV injection of NPY in goldfish
increases feeding (Volkoff et al., 2009). In trout, ICV administra-
tion of trout NPY and PYY at doses up to 100 pmol does not have
any effect on ventilatory and cardiovascular variables (unpub-
lished data). These cardiovascular results are consistent with a
previous study demonstrating that ICV injection of human NPY
(0.6–0.8 nmol) in trout exerts only a weak hypertensive action
without any change in HR (Le Mével et al., 1991). These results
obtained in trout suggest that, contrary to the actions of the other
peptides mentioned in this review, NPY and PYY do not appear
to have an important role in the central cardiorespiratory regu-
lation in trout. In contrast, cod NPY causes vasodilation in the
cod celiac artery (Shahbazi et al., 2002). In the elasmobranchs,
the unanesthetized Scyliorinus canicula (Conlon et al., 1991) and
the anesthetized Heterodontus portjacksoni (Preston et al., 1998),
IA or intravenous injection of relatively high doses of dogfish NPY
or PYY significantly increase blood pressure. However in trout, IA
injection of trout NPY and PYY at a 100 pmol dose is devoid of
significant cardiovascular effects (unpublished data). These dif-
ferences between the effects of NPY and PYY in elasmobranchs
and teleosts can possibly be explained by the different experimen-
tal protocols used or that the location of NPY/PYY cardiovascular
receptors in the cardiovascular systems of elasmobranchs differs
from that in teleost fishes.
POSSIBLE MECHANISMS OF ACTION AND PHYSIOLOGICAL
SIGNIFICANCE
In order to produce changes in ventilatory and cardiovas-
cular variables, ICV injections of neuropeptides must access
receptors critical for the control of cardio-ventilatory motor
neurons. However, the receptor site(s) initiating cellular trans-
duction mechanisms cannot be deduced from the experiments
in which the peptides are injected into the third cerebral ven-
tricle. Nevertheless, neuroanatomical prerequisites and some
neurophysiological data exist that might explain the ventilatory
and cardiovascular responses to ICV neuropeptides. Since the
neuropeptides are injected in close proximity to a major neu-
roendocrine hypothalamic nucleus, the NPO, it is reasonable to
assume that these exogenous neuropeptides maymimic the action
of the endogenous peptides after release from neurons belonging
to this nucleus. These neuropeptides can then activate arginine
vasotocin (AVT) and isotocin (IT) preoptic neurons. AVT and
IT preoptic neurons project to the neurohypophysis where the
two nonapeptides are released into the general circulation. AVT
is well known to increase vascular tone and elevate blood pres-
sure in vivo (Le Mével et al., 1996; Conklin et al., 1997). In
addition to this neuroendocrine pathway, projection from the
preoptic neurons could influence brainstem respiratory and car-
diovascular neurons including the NTS and the DVN through
the neurogenic route by the release of AVT, IT or other neu-
ropeptides or classical neurotransmitters (Batten et al., 1990; Saito
et al., 2004). In the goldfish, functional-anatomical studies have
demonstrated the existence of a neural pathway from the pre-
optic area to the DNV controlling concomitantly ventilation and
HR (Hornby and Demski, 1988). In mammals, stimulation of the
FIGURE 3 | A model based on a parasagital view of the CNS of the
trout depicting the potential central sites and pathways for the effects
of intracerebroventricular administered neuropeptides (NPs) on central
ventilatory and cardiovascular functions. Target ventilatory and
cardiovascular tissues are also shown. Projecting fibers from preoptic
nucleus (NPO) neurons to brainstem ventilatory and cardiovascular nuclei
and to spinal sympathetic neurons (sn) are shown with a bold hatched
line. Motor outputs from ventilatory and cardiovascular central nuclei to
peripheral effectors are shown in continuous line. Feedback information
from peripheral tissues to CNS nuclei is shown using thin hatched lines.
The sites and pathways described are highly schematic and speculative
(see also text in section 2 and 5 for further explanations). Other
abbreviations: AVT, arginine-vasotocin; Cb, cerebellum; CPG, central pattern
generator; CNSS, caudal neurosecretory system; De, diencephalon; DVN,
dorsal motor nucleus of the vagus; Hy, hypothalamus; MC, massa caudalis;
Me, mesencephalon; NTS, nucleus tractus solitarius; OB, olfactory bulb;
ON, optic nerve; OT, optic tectum; Pit, pituitary gland (hypophysis); rmn,
respiratory motor nuclei; Te, telencephalon; Ur, urophysis; VC, valvula
cerebelli. V, trigeminal; VII, facial; IX, glossopharyngeal; X, vagal cranial
nerves.
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PVN, a nucleus homologous to the teleostean NPO, can influ-
ence brainstem and spinal cord respiratory related mechanisms.
Vasopressin and oxytocin parvocellular neurons of the PVN
project to important respiratory-related regions of the medulla
and spinal cord, including the pre-Bõtzinger complex and the
phrenic motor nuclei (Mack et al., 2002). The PVN is also part
of the central cardiovascular network that controls the rostral
ventrolateral medulla (RVLM) (Nunn et al., 2011). Neurons of
the RVLM send excitatory projections to the sympathetic pre-
ganglionic neurons in the intermediolateral cell column of the
spinal cord to increase HR and blood pressure (Dampney et al.,
2005; Pilowsky et al., 2009; Nunn et al., 2011). Although in fish
the locations of sympathetic pre-vasomotor nuclei within the
medulla are unknown, neuropeptides may also act at the medulla
oblongata to influence sympathetic outflow to vascular tissue and
chromaffin cells increasing blood pressure. In addition, we can
speculate about a possible diffusion of the injected neuropep-
tides within the cerebrospinal fluid toward critical ventilatory and
cardiovascular brainstem nuclei. Consistent with this, receptors
for some of the aforementioned neuropeptides are also expressed
within the hindbrain (Cobb and Brown, 1992; Moons et al.,
1992; Lovejoy and Balment, 1999; Lu et al., 2006). However, the
pharmacological characterization of these receptors using spe-
cific antagonists/agonists is difficult in fish due to the fact that
only drugs designed for mammalian receptors are available. We
have noted consistently that the effects exerted by the neuropep-
tides are usually long lasting, a characteristic that is probably
related to their slow rate of metabolism. Alternatively, this long
lasting effect of neuropeptides may be due to complex intra-
cellular signalling pathways after binding to their metabotropic
GPCRs.
We cannot excluded that some neuropeptides when injected
at high doses within the periphery may act at central target
sites to increase PDA, through leakage of the blood brain bar-
rier. However, a direct action of neuropeptides on vasculature is
probably the physiological mechanism involved after peripheral
injection.
Figure 3 gives a summary of the proposed mechanisms for
central neuropeptidergic cardio-respiratory regulation in trout.
Table 1 provides a summary of the central ventilatory and
cardiovascular actions of neuropeptides in our trout model.
However, it remains to be determined whether the observed
actions of exogenously administered neuropeptides can be trans-
lated into evidence for endogenous regulation of physiological
functions. It is probable that a cocktail of neuropeptides within
the trout brain is involved in fine control of ventilation, each
peptide having a selective action either on VA or VF or on
both ventilatory variables. Neuropeptides may be part of the
neurochemical systems that are involved in the hypoxic venti-
latory response in fish (Porteus et al., 2011). However, as pre-
viously stated, their precise implication in the CNS pathways
that control the VA and VF during intermittent, repeated or
chronic hypoxia is unknown. A balance between the action of
hyperventilatory and hypoventilatory peptides may permit the
fine control of ventilation so as to maintain homeostasis. In
addition, endogenous neuropeptides may regulate cardiovascular
function.
Table 1 | Summary of the effects of intracerebroventricular injection




VF VA VTOT PDA HR
PACAP (50) – – –
(100) –
VIP (50) – – – – –
(100) – – – –
NPγ (50) – –
(100) – –
SP (100) – – – – –
(250) – –
NKA (100) – – – – –
(250) – – –
CRF (5) –
(10) –
U-I (5) – – – – –
(10) –
CGRP (5) – –
(50) –
[Asn1]-Ang II (5) – – – –
(50) –
[Asp1]-Ang II (5) – – – – –
(50) –
Ang III (50) – – –
(100) – – –
Ang IV (100) – – – – –
Ang 1–7 (100) – – – – –
U II (5) – – – – –
(50) –
NPY (100) – – – – –
PYY (100) – – – – –
PACAP, pituitary adenylate cyclase-activating polypeptide; VIP, vasoactive
intestinal peptide; NPγ, neuropeptide gamma; SP, substance P; NKA, neurokinin
A; CRF, corticotropin-releasing factor; U-I, urotensin-I; CGRP, calcitonin gene-
related peptide; [Asn1]-Ang II, [Asn1]-angiotensin II; [Asp1]-Ang II, [Asp1]-
angiotensin II; Ang III, angiotensin III; Ang IV, angiotensin IV; Ang 1–7, angiotensin
1–7; U-II, urotensin-II; NPY, neuropeptide Y; PYY, peptide YY. –, no effect;
, increase; , decrease; symbol in bold reflects a higher effect.
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The circumstances leading to the release of endogenous
neuropeptides into the synaptic cleft to control the venti-
latory and cardiovascular autonomic nuclei during adverse
metabolic or environmental situations remain to be delin-
eated. It may be hypothesized that the central neuropeptider-
gic regulation of cardio-respiratory functions may be critical
for proper uptake of oxygen from the aquatic environment
and distribution of oxygen to tissues during hypoxic stress
for example. Hypoxic stress is known to induce an hyper-
ventilatory response in the rainbow trout through a selective
action on VA (Gilmour and Perry, 2007) and environmen-
tal hypoxia increases the expression of CRF, UI, and CRF-
binding protein genes within the NPO (Bernier and Craig,
2005).
CONCLUSION AND PERSPECTIVES
Besides conservation of the amino acid sequence of neuropeptides
during evolution, our physiological results obtained with unanes-
thetized trout also give support for a strong conservation of car-
diovascular and ventilatory functions throughout the vertebrate
classes. Determination of the central ventilatory and cardiovas-
cular actions of these neuropeptides in our trout model suggests
that these neuropeptides act as neuromodulators and/or neuro-
transmitters. In addition, neuropeptides acting as local peptides
or hormonesmay be involved in peripheral cardiovascular regula-
tion. We hope that our comparative physiological studies provide
new insights into evolution of the basic neuroregulatory mecha-
nisms that operate in the CNS of vertebrates, including humans,
to control these vital cardio-respiratory functions.
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